|
1
|
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
|
N Engl J Med
|
2002
|
5.58
|
|
2
|
A single cycle of rituximab for the treatment of severe pemphigus.
|
N Engl J Med
|
2007
|
2.41
|
|
3
|
Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response.
|
Sci Transl Med
|
2010
|
2.28
|
|
4
|
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
|
Am J Clin Pathol
|
2005
|
2.15
|
|
5
|
B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses.
|
J Invest Dermatol
|
2008
|
2.10
|
|
6
|
Poor benefit/risk balance of intravenous immunoglobulins in DRESS.
|
Arch Dermatol
|
2012
|
1.71
|
|
7
|
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
|
Eur J Cancer
|
2006
|
1.38
|
|
8
|
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.
|
J Invest Dermatol
|
2009
|
1.26
|
|
9
|
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
|
Sci Transl Med
|
2013
|
1.15
|
|
10
|
Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
|
J Clin Oncol
|
2008
|
1.15
|
|
11
|
Neurological disorders in patients with bullous pemphigoid.
|
Dermatology
|
2007
|
1.14
|
|
12
|
Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
|
Clin Cancer Res
|
2010
|
1.07
|
|
13
|
Azo pigments and quinacridones induce delayed hypersensitivity in red tattoos.
|
Contact Dermatitis
|
2014
|
0.96
|
|
14
|
CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
|
J Invest Dermatol
|
2004
|
0.95
|
|
15
|
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.
|
Blood
|
2004
|
0.93
|
|
16
|
Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination.
|
Biochim Biophys Acta
|
2008
|
0.93
|
|
17
|
Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature.
|
Transfusion
|
2007
|
0.90
|
|
18
|
123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.
|
Eur J Nucl Med Mol Imaging
|
2002
|
0.89
|
|
19
|
B16 melanoma secretomes and in vitro invasiveness: syntenin as an invasion modulator.
|
Melanoma Res
|
2010
|
0.86
|
|
20
|
(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
|
J Nucl Med
|
2013
|
0.86
|
|
21
|
Annexin A1 in primary tumors promotes melanoma dissemination.
|
Clin Exp Metastasis
|
2014
|
0.84
|
|
22
|
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
|
J Invest Dermatol
|
2004
|
0.82
|
|
23
|
Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.
|
J Am Acad Dermatol
|
2011
|
0.81
|
|
24
|
UV-B phototoxic effects induced by atorvastatin.
|
Arch Dermatol
|
2006
|
0.81
|
|
25
|
Acquired angioedema responding to rituximab.
|
Acta Derm Venereol
|
2011
|
0.81
|
|
26
|
Ichthyosiform mycosis fungoides.
|
Eur J Dermatol
|
2002
|
0.81
|
|
27
|
Use of cryopreserved autologous cells for extracorporeal photochemotherapy: clinical applications.
|
Transfusion
|
2011
|
0.79
|
|
28
|
Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma.
|
Anticancer Res
|
2009
|
0.78
|
|
29
|
A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer.
|
Anticancer Res
|
2007
|
0.78
|
|
30
|
Optimal methionine-free diet duration for nitrourea treatment: a Phase I clinical trial.
|
Nutr Cancer
|
2008
|
0.78
|
|
31
|
Rituximab for pemphigus vulgaris.
|
N Engl J Med
|
2007
|
0.78
|
|
32
|
Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.
|
JAMA Dermatol
|
2014
|
0.77
|
|
33
|
A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis.
|
Chest
|
2014
|
0.77
|
|
34
|
Extracorporeal photochemotherapy for graft versus host disease in pediatric patients.
|
Transfus Apher Sci
|
2003
|
0.76
|
|
35
|
Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.
|
BMC Cancer
|
2005
|
0.76
|
|
36
|
Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
|
Arch Dermatol
|
2005
|
0.76
|
|
37
|
Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients.
|
J Hematother Stem Cell Res
|
2002
|
0.75
|
|
38
|
High Prevalence of Personality Disorders in Skin-restricted Lupus Patients.
|
Acta Derm Venereol
|
2017
|
0.75
|
|
39
|
Eagle syndrome, a rare cause of glossodynia.
|
Eur J Dermatol
|
2012
|
0.75
|
|
40
|
[Therapy algorithm for cutaneous T-cell lymphomas].
|
Ann Dermatol Venereol
|
2005
|
0.75
|
|
41
|
Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
|
Arch Dermatol
|
2009
|
0.75
|
|
42
|
Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial.
|
Anticancer Drugs
|
2005
|
0.75
|